Navigation Links
InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
Date:4/20/2009

-- Conference Call and Webcast Scheduled --

BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in the discussion will be Ed Gane, M.D., principal investigator in the INFORM-1 trial. Members of management from Roche, InterMune and Pharmasset will also be available to answer questions.

Dial-In and Webcast Details

A live webcast and slide presentation will be available through the Investor Relations pages of both InterMune and Pharmasset at www.intermune.com or www.pharmasset.com, respectively. Alternatively, interested parties may access the discussion and ask questions by dialing 888-799-0528 (U.S. & Canada) or 973-200-3372 (International), conference ID # 95452531. A webcast replay will be available approximately three hours after the call and will be archived at www.intermune.com and at www.pharmasset.com.

The companies recommend logging on at least 15 minutes prior to the start of the webcast to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S. & Canada) or 706-645-9291 (international), and entering conference ID # 95452531.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):